These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 33032860)

  • 1. Increased flexibility in methadone take-home scheduling during the COVID-19 pandemic: Should this practice be incorporated into routine clinical care?
    Trujols J; Larrabeiti A; Sànchez O; Madrid M; De Andrés S; Duran-Sindreu S
    J Subst Abuse Treat; 2020 Dec; 119():108154. PubMed ID: 33032860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19.
    Figgatt MC; Salazar Z; Day E; Vincent L; Dasgupta N
    J Subst Abuse Treat; 2021 Apr; 123():108276. PubMed ID: 33612201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revising our attitudes towards agonist medications and their diversion in a time of pandemic.
    Del Pozo B; Rich JD
    J Subst Abuse Treat; 2020 Dec; 119():108139. PubMed ID: 33138924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving methadone access for rural communities in the USA: lessons learned from COVID-19 adaptations and international models of care.
    Lister JJ; Lister HH
    Rural Remote Health; 2021 Nov; 21(4):6770. PubMed ID: 34757760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acceptability, feasibility, and outcomes of a clinical pilot program for video observation of methadone take-home dosing during the COVID-19 pandemic.
    Hallgren KA; Darnton J; Soth S; Blalock KL; Michaels A; Grekin P; Saxon AJ; Woolworth S; Tsui JI
    J Subst Abuse Treat; 2022 Dec; 143():108896. PubMed ID: 36215911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experience of patients on methadone maintenance treatment receiving take-home methadone doses during COVID-19 pandemic: A multi-site study from India.
    Kathiresan P; Patel V; Jangra J; Chattopadhyay A; Abdus S; Jadhav M; Rao R; Arya A; Bansal PD; Chinggouman C; Bhad R; Ambekar A; Agrawal A; Chatterjee B; Yadav D
    Asian J Psychiatr; 2024 May; 95():103979. PubMed ID: 38442535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges of methadone maintenance treatment during the COVID-19 epidemic in China: Policy and service recommendations.
    Jiang H; Su H; Zhang C; Liu X; Li R; Zhong N; Zhao M
    Eur Neuropsychopharmacol; 2020 Jun; 35():136-137. PubMed ID: 32307223
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: A mixed methods analysis.
    Hoffman KA; Foot C; Levander XA; Cook R; Terashima JP; McIlveen JW; Korthuis PT; McCarty D
    J Subst Abuse Treat; 2022 Oct; 141():108801. PubMed ID: 35589443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing Medication Treatment of Opioid Use Disorder During COVID-19 (SARS-CoV-2).
    Leppla IE; Gross MS
    J Addict Med; 2020; 14(4):e1-e3. PubMed ID: 32412931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TIME TO REVISIT UNEVEN POLICY IN THE UNITED STATES FOR MEDICATION FOR OPIOID USE DISORDER DURING COVID-19.
    Pena E; Ahmed S
    Addiction; 2020 Oct; 115(10):1978-1979. PubMed ID: 32447795
    [No Abstract]   [Full Text] [Related]  

  • 11. COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership.
    Levander XA; Pytell JD; Stoller KB; Korthuis PT; Chander G
    Subst Abus; 2022; 43(1):633-639. PubMed ID: 34666636
    [No Abstract]   [Full Text] [Related]  

  • 12. Technology-assisted methadone take-home dosing for dispensing methadone to persons with opioid use disorder during the Covid-19 pandemic.
    Dunn KE; Brooner RK; Stoller KB
    J Subst Abuse Treat; 2021 Feb; 121():108197. PubMed ID: 33357606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study.
    Oviedo-Joekes E; MacDonald S; Boissonneault C; Harper K
    Subst Abuse Treat Prev Policy; 2021 Mar; 16(1):22. PubMed ID: 33673847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "No home to take methadone to": Experiences with addiction services during the COVID-19 pandemic among survivors of opioid overdose in Boston.
    Harris MTH; Lambert AM; Maschke AD; Bagley SM; Walley AY; Gunn CM
    J Subst Abuse Treat; 2022 Apr; 135():108655. PubMed ID: 34772604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re-thinking patient stability for methadone in opioid treatment programs during a global pandemic: Provider perspectives.
    Hatch-Maillette MA; Peavy KM; Tsui JI; Banta-Green CJ; Woolworth S; Grekin P
    J Subst Abuse Treat; 2021 May; 124():108223. PubMed ID: 33342667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A chance to do it better: Methadone maintenance treatment in the age of Covid-19.
    Frank D
    J Subst Abuse Treat; 2021 Apr; 123():108246. PubMed ID: 33612189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment provider perceptions of take-home methadone regulation before and during COVID-19.
    Madden EF; Christian BT; Lagisetty PA; Ray BR; Sulzer SH
    Drug Alcohol Depend; 2021 Nov; 228():109100. PubMed ID: 34600251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic.
    Cochran G; Bruneau J; Cox N; Gordon AJ
    Subst Abus; 2020; 41(3):269-274. PubMed ID: 32697171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19.
    Brothers S; Viera A; Heimer R
    J Subst Abuse Treat; 2021 Dec; 131():108449. PubMed ID: 34098303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating how has care been affected by the Ontario COVID-19 Opioid Agonist Treatment Guidance: Patients' and prescribers' experiences with changes in unsupervised dosing.
    Corace K; Suschinsky K; Wyman J; Leece P; Cragg S; Konefal S; Pana P; Barrass S; Porath A; Hutton B
    Int J Drug Policy; 2022 Apr; 102():103573. PubMed ID: 35123246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.